Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3134124 | 1.00 | CYP3A4 (0.34) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL908387 | 0.89 | ABCB1 (0.35) | CYP3A4 | |
| SCHEMBL909010 | 0.86 | CTSS (0.32) | CYP3A4 | |
| SCHEMBL909009 | 0.86 | CTSS (0.32) | CYP3A4 | |
| SCHEMBL3135181 | 0.84 | CYP3A4 (0.35) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL3139064 | 0.84 | CYP3A4 (0.35) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL3135186 | 0.84 | CYP3A4 (0.35) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL908388 | 0.76 | CYP3A4 (0.31) | CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL908975 | 0.75 | ALDH1A1 (0.32) | CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL908364 | 0.75 | ALDH1A1 (0.32) | CYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453000-B2 | Polycyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| EP-2181992-B1 | POLYCYCLIC COMPOUND | EISAI R&D MAN CO LTD (JP) | 2013-05-01 | — | — | EP | disclosed |
| EP-2559693-A1 | Polycyclic compound | Eisai R&D Management Co., Ltd. (JP) | 2013-02-20 | — | — | EP | disclosed |
| US-20110065696-A1 | IMIDAZOYL PYRIDINE COMPOUNDS AND SALTS THEREOF | KIMURA TEIJI | 2011-03-17 | — | — | US | disclosed |
| EP-2181992-A1 | POLYCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065696-A1 | IMIDAZOYL PYRIDINE COMPOUNDS AND SALTS THEREOF | APP, PSEN1, BACE1 | CYP3A4 767/4885HTT 6/4885SMN1; SMN2 288/4885 |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | APP, BACE1, PSEN1 | CYP3A4 2999/4885HTT 10/4885SMN1; SMN2 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.